BAFFR-CAR T cells

BIOLOGICAL2 trials

Sponsors

PeproMene Bio, Inc.

Conditions

Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

Active, not recruitingNCT04690595

PeproMene Bio, Inc.Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Start: 2021-05-18End: 2027-11-18Target: 24Updated: 2026-02-11

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

RecruitingNCT05370430

PeproMene Bio, Inc.Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Start: 2022-06-13End: 2028-06-13Target: 36Updated: 2025-11-20

Related Papers

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Blood2025-11-03

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

Blood2025-11-03

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Blood2024-11-052 citations

Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies

Blood Advances2024-06-172 citations

PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.

Journal of Clinical Oncology2024-06-014 citations

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

Blood2023-11-023 citations

CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia

Blood2021-11-053 citations